TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+6.47%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.7B
AUM Growth
+$2.7B
(+4.7%)
Cap. Flow
-$19.8M
Cap. Flow
% of AUM
-0.73%
Top 10 Holdings %
Top 10 Hldgs %
44.18%
Holding
152
New
13
Increased
22
Reduced
28
Closed
8
Top Buys
| 1 |
Merck
MRK
|
$17.6M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
$14.5M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$14.1M |
| 4 |
Novartis
NVS
|
$12.5M |
| 5 |
Biogen
BIIB
|
$12.2M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$30.3M |
| 2 |
Molina Healthcare
MOH
|
$18.4M |
| 3 |
Thermo Fisher Scientific
TMO
|
$15.5M |
| 4 |
Pfizer
PFE
|
$11.3M |
| 5 |
Health Care Select Sector SPDR Fund
XLV
|
$10.5M |
Sector Composition
| 1 | Healthcare | 91.69% |
| 2 | Real Estate | 3.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $189M | 7.01% | 1,456,605 +90,000 | +7% | +$11.7M |
|
2
Gilead Sciences
GILD
$140B
| $179M | 6.63% | 2,530,131 | – | – |
|
|
3
Biogen
BIIB
$19.4B
| $144M | 5.33% | 529,774 +44,800 | +9% | +$12.2M |
|
4
Amgen
AMGN
$155B
| $118M | 4.37% | 684,824 | – | – |
|
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $103M | 3.81% | 798,053 -235,450 | -23% | -$30.3M |
|
6
Johnson & Johnson
JNJ
$427B
| $94.5M | 3.5% | 714,362 | – | – |
|
|
7
Merck
MRK
$210B
| $94.4M | 3.5% | 1,473,295 +274,946 | +23% | +$17.6M |
|
8
Regeneron Pharmaceuticals
REGN
$61.5B
| $92.2M | 3.41% | 187,666 | – | – |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $91.4M | 3.38% | 750,905 -45,000 | -6% | -$5.48M |
|
10
Incyte
INCY
$16.5B
| $87.3M | 3.23% | 693,275 | – | – |
|
|
AGN
11
DELISTED
Allergan plc
AGN
| $75.5M | 2.8% | 310,610 | – | – |
|
12
Viatris
VTRS
$12.3B
| $62.2M | 2.31% | 1,603,112 +52,700 | +3% | +$2.05M |
|
13
UnitedHealth
UNH
$281B
| $57M | 2.11% | 307,476 +624 | +0.2% | +$116K |
|
14
Abbott
ABT
$231B
| $56M | 2.08% | 1,152,520 | – | – |
|
15
Medtronic
MDT
$119B
| $51.5M | 1.91% | 580,326 -32,704 | -5% | -$2.9M |
|
16
Illumina
ILMN
$15.8B
| $48.4M | 1.79% | 278,960 -18,400 | -6% | -$3.19M |
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $45.6M | 1.69% | 501,745 -4,100 | -0.8% | -$372K |
|
18
Jazz Pharmaceuticals
JAZZ
$7.75B
| $42.6M | 1.58% | 273,916 -57,495 | -17% | -$8.94M |
|
|
SHPG
19
DELISTED
Shire pic
SHPG
| $41.7M | 1.54% | 252,113 +20,700 | +9% | +$3.42M |
|
20
Eli Lilly
LLY
$657B
| $40.6M | 1.5% | 493,100 | – | – |
|
21
Teva Pharmaceuticals
TEVA
$21.1B
| $33.7M | 1.25% | 1,015,758 | – | – |
|
|
22
Novartis
NVS
$245B
| $33.3M | 1.23% | 398,662 +149,862 | +60% | +$12.5M |
|
23
CVS Health
CVS
$92.8B
| $33.1M | 1.23% | 411,891 | – | – |
|
24
Humana
HUM
$36.5B
| $30M | 1.11% | 124,781 -29,019 | -19% | -$6.98M |
|
|
25
Pfizer
PFE
$141B
| $27.2M | 1.01% | 810,087 -336,602 | -29% | -$11.3M |
|